End to End CRDMO Platform for 
Drugs
- Select
-
Home | Services & Solutions | Peptide
WuXi TIDES’s peptide platform offers comprehensive CRDMO from drug discovery to commercial manufacturing for both drug substance and drug product.
Our peptide discovery synthesis service platform provides high throughput library synthesis and custom synthesis. We support all types of peptides, including linear, cyclic and highly modified peptides, and UAA, linkers, toxins and peptide conjugates. Additionally, we provide dedicated analytical support for all required tests, including unique enantiomeric analysis.
We can seamlessly scale up to any scale to meet various demands from preclinical, clinical to commercial stages with ample capacities and proven capabilities with commercial success. The total reactor volume for Solid Phase Peptide Synthesis (SPPS) is over 41,000 L.
Beyond chemistry, we provide formulation development and manufacturing services with various oral and injectable dosage forms and filling formats. These services are coupled with comprehensive analytical support for both drug substance and drug product under one quality system, as well as the integrated CMC dossier preparation services, enabling our customers to bring their peptide therapeutics to market faster.
Peptide CRDMO Chemistry Platform
from Discovery to Development and Commercial Manufacturing
Unnatural Amino Acid
- α,β,γ-substituted
- N-alkylated
- Glycosylation
Peptide
- Long Linear
- Cyclic
- Modified
- PEGylated
- Peptidomimetics
Conjugate
- Peptide-PMO (PPMO)
- Peptide-Oligonucleotide (POC)
- Peptide-Drug (PDC)
- Radionuclide Drug (RDC)
Services and Solutions
Discovery Synthesis
Development & Manufacturing
Why WuXi TIDES?
Dont edit
Scalability
Conjugation Chemistry
Seamless collaboration across oligonucleotide, peptide and small molecule teams
New Technology
Reactor-in-series (with PAT data collection) , continues flow chromatography, Tangential Flow Filtration (TFF) / precipitation
Global Quality Standard
One quality system across all sites approved by major regulatory agencies around the world
Comprehensive Analytical Platform
Method development and validation, IPC and release testing, characterization, stability
Integrated CMC
API Process R&D and Manufacturing, Formulation Development and Manufacturing, Analytical, CMC Dossier Preparation and Clinical Supply Services
Meeting global quality standard
16
US FDA Inspections
2013-2024
7
EU EMA Inspections
2009-2024
53
China NMPA Inspections
2015-2024
9
Japan PMDA Inspections
2019-2024
4
South Korea MFDS Inspections
5
SwissMedic Inspections
2018-2024
